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Abstract: Telomeres consist of repeat DNA sequences located at the terminal portion of chromosomes
that shorten during mitosis, protecting the tips of chromosomes. During chronic degenerative
conditions associated with high cell replication rate, progressive telomere attrition is accentuated,
favoring senescence and genomic instability. Several lines of evidence suggest that this process
is involved in liver disease progression: (a) telomere shortening and alterations in the expression
of proteins protecting the telomere are associated with cirrhosis and hepatocellular carcinoma;
(b) advanced liver damage is a feature of a spectrum of genetic diseases impairing telomere function,
and inactivating germline mutations in the telomerase complex (including human Telomerase Reverse
Transcriptase (hTERT) and human Telomerase RNA Component (hTERC)) are enriched in cirrhotic patients
independently of the etiology; and (c) experimental models suggest that telomerase protects from
liver fibrosis progression. Conversely, reactivation of telomerase occurs during hepatocarcinogenesis,
allowing the immortalization of the neoplastic clone. The role of telomere attrition may be particularly
relevant in the progression of nonalcoholic fatty liver, an emerging cause of advanced liver disease.
Modulation of telomerase or shelterins may be exploited to prevent liver disease progression, and to
define specific treatments for different stages of liver disease.
Keywords: telomere; telomerase; liver disease progression; nonalcoholic fatty liver disease; cirrhosis;
hepatocellular carcinoma
1. Introduction
In humans, telomeres consist of thousands copies of six base repeats (TTAGGG) located at the
extremities of the chromosomes that protect chromosomes tips from end-to-end fusion, rearrangement
and translocation. Telomere length is progressively shortened at each mitosis, due to the inability of the
DNA polymerase complex to replicate the very 51 end of the lagging strand (attrition). For this reason,
telomere shortening may function as a “mitotic clock” to sense somatic cells aging. When telomeres
become critically short, a DNA-damage program is activated, leading to apoptosis or cell senescence.
On the contrary, immortal cells (cancer, stem and germ cells) constitutionally express telomerase, a
ribonuclear enzymatic complex associated with telomeres that is responsible for stabilizing telomere
length by synthesizing new DNA sequences and adding them to the end of the chromosomes during
DNA replication [1]. Telomerase comprises two essential components: Telomerase reverse transcriptase
(hTERT) and its RNA template, the telomerase RNA component (hTERC). Dyskerin complex binds to
hTERC, in order to protect it and to stabilize the telomerase complex. It includes four nucleolar proteins:
Dyskerin (DKC1) and Nucleolar protein family A member 1, 2 and 3 (NOLA1-NOLA2-NOLA3) [2–4].
Besides telomerase, the Shelterin complex, which binds specifically to telomeres, plays a fundamental
role in the protection of chromosome ends facilitating telomerase-based telomere elongation [5]. It
is composed of six core proteins: the telomeric repeat binding factors 1 and 2 (TRF1-TRF2) that bind
telomeric double strand DNA, the protection of telomeres 1 (POT1), which binds the 31 telomeric region
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of single strand DNA avoiding the degradation by nuclease, and the TRF-1 interacting protein 2 (TIN2),
the POT1-TIN2 organizing protein (TPP1) and the repressor/activator protein 1 (RAP1), that interact
with the other proteins bound to telomere stabilizing the complex (Figure 1; [6,7]). Mutations of proteins
involved in maintenance and repair of telomeres are responsible for telomeropathies [8,9]: a spectrum
of progressive genetic diseases exemplified in the most severe cases by dyskeratosis congenita (DKC),
whose common autosomal recessive form is caused by mutations in DKC1. They are degenerative
and age-dependent diseases, characterized by premature senescence of the stem cell compartment,
determining increased risk of organ failure and cancer, with possible involvement of the hematopoietic
compartment, lungs, mucous membranes, skin, and also the liver. Consistently, loss-of-function
mutations in hTERT and hTERC may cause a spectrum of familial liver diseases [10]. Telomere length
is a strong hereditable tract and telomere shortening is accentuated in chronic degenerative condition
associated with high cell replication rate. Thus, involvement of telomeres and telomerase mutations
seems to be important in predisposition to liver disease progression towards hepatocellular carcinoma
(HCC). Indeed, the incidence of HCC increases with age, and, in particular, in nonalcoholic fatty liver
disease (NAFLD), where there is a strong aggregation of familial cases [11].
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participating in tissue regeneration. Thus, the regenerative potential of an organ depends on the size 
of the population of cells with sufficient telomere reserves required for cell proliferation. 
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cells with sufficient telomere reserves required for cell proliferation. Consistently, in chronic disease
associated with tissue regeneration, such as cirrhosis, an elevated regenerative pressure is generated
on the proliferating subpopulation of cells, which undergoes several rounds of cell division that, in
turn, accelerate the rate of telomere shortening [14]. When telomeres become critically short, a DNA
damage program is activated, leading to cell senescence or apoptosis (due to the Hayflick limit), further
reducing the number of cell with regenerative capacity.
Several lines of evidence correlate shortened telomeres with liver fibrosis. Kitada et al. [15] first
described a progressive reduction of telomere length during liver disease progression. Urabe et al. [16]
confirmed these data and described telomerase re-activation in poorly differentiated HCC, consistently
with an increase of telomere length compared to those well differentiated. In the normal liver,
progressive telomere shortening has been correlated with age. Consistently, reduction of telomere
length in cirrhotic tissue was more marked in patients who developed cirrhosis at younger age [17].
Additionally, reduction of telomere length is considered a hallmark of cirrhotic tissue independently
of the etiology of liver disease (e.g., viral hepatitis, autoimmune hepatitis, alcohol abuse . . . ) [18].
Thus, excessive telomere shortening, caused either by telomerase gene mutations or acquired factors,
may impair the hepatocyte regenerative ability in response to chronic injury, facilitating fibrosis
progression [19,20]. A causal role of telomere shortening in fibrosis progression has been experimentally
demonstrated in telomerase deficient mice. After three generations, these mice developed shortened
telomeres and displayed diminished capacity for liver regeneration, and with accelerated development
of cirrhosis after liver injury. On the contrary, overexpression of TERT activity improved liver function
and protected mice from development of hepatic steatosis and fibrosis [21].
Consistently, shortened telomere length in cirrhotic patients was correlated with the expression
of known markers of cellular senescence, such as β-galactosidase, p16, p21 and p53 not only in
hepatocytes but also in non-parenchymal cells, such as biliary cells [22,23]. The p53 protein represents
the key regulator point for various signaling pathways of senescence: p53 phosphorylation and
consequent activation inhibits cell division primarily inducing p21 expression, which, in turn, activates
pRb through inhibition of a cyclin-dependent kinase (Cdk) complex. The activated pRb inhibits the
transcription of E2F target genes that are required for cell cycle progression. pRB can alternatively be
activated by p16, another Cdk inhibitor, that typically accumulates in senescent cells [23].
Cellular senescence may have a dual role in liver disease: in a first phase, it seems to contribute to
liver impairment by reducing the hepatocytes and progenitor cell population, while, in a second phase,
the subsequent senescence of HSC (epatic stellate cells) due to long-standing activation of fibrogenesis
may protect from further fibrosis progression [24–26]. In particular, progression of human fibrosis is
often characterized by a state of chronic inflammation that results in a condition of cell death and tissue
regeneration, involving also a massive expansion of hepatic progenitor cells in order to restore the
lost hepatocytes. Ductular reaction typical of this condition has been shown to produce chemotactic
stimuli for induction of inflammatory cells and activation of pro-fibrotic hepatic stellate cells (HSC).
Moreover, due to the epithelial to mesenchymal transition, progenitors and biliary epithelial cells may
provide a portion of myofibroblasts, contributing to fibrosis progression [27]. When the wound is
filled, the activated HSC undergo apoptosis or cellular senescence and consequently are eliminated by
immune cells. In this way, HSC induce the recruitment of other immune cells at the site of tissue injury
that, in turn, help in arresting liver fibrosis progression. However, it has recently been shown that later,
senescent HSC may favor HCC development by secreting pro-carcinogenic mediators (the senescence
associated secretory program: SASP) [28].
2.2. Telomerase Mutations Are Hallmarks of Liver Fibrosis
Genetic studies have proven that mutations in telomerase represent the underlying cause of
accelerated telomere shortening and organ failure in some rare human diseases, including some
forms of DKC [29], which may be characterized by liver injury and development of complications
of portal hypertension. Moreover, evidence suggests that telomere attrition is also involved in liver
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disease progression in humans. Indeed, a spectrum of familial liver disease with autosomal dominant
transmission and incomplete penetrance has been associated with inheritance of hTERT and hTERC
mutations [10,30]. In these pedigrees, liver disease was characterized by development of steatosis,
with possible progression to cirrhosis and HCC. Furthermore, a significant enrichment of missense
mutations in the hTERT and hTERC genes was observed in 7% of patients and one patient, respectively,
of a US cohort including 134 patients with cirrhosis of different etiologies (NAFLD, but also alcohol
abuse and Hepatitis C virus infection), as compared to healthy controls. These mutations impaired
hTERT enzymatic activity, as they were associated with reduced telomere length in the peripheral blood
of patients and reduced telomerase activity in vitro [19]. These data were substantially confirmed in a
larger series of 521 German patients with cirrhosis, of whom 3% carried functional hTERT mutations
again independently from the etiology of the liver disease [31]. These observations indicate that, in at
least a proportion of patients who developed cirrhosis, fibrosis progression may be favored by genetic
risk variants facilitating telomere shortening and cell senescence in the presence of triggering factors.
2.3. Telomere Shortening Induces Genomic Instability in Hepatocellular Carcinoma (HCC)
Thus, telomere shortening is a hallmark of cirrhosis, the main risk factor for the development
of liver cancer [32]. The state of chronic inflammation characteristic of injured liver, results per se
in oxidative DNA damage leading to genomic and epigenomic alterations, pushing cells toward a
malignant phenotype. Deregulation of key oncogenes and tumor-suppressor genes, such as TP53,
β-catenin, ErbB receptor family members and p16(INK4a) have been observed both in early and advance
HCC. Impaired function of p53 most likely induces alterations in DNA damage response machinery,
resulting in loss of DNA repairing and avoiding cellular apoptosis, thus contributing to an increased
mutation rate. Moreover, aberrant DNA methylation patterns have been reported in the earliest stages
of hepatocarcinogenesis, and to a greater extent in tumor progression. Finally, karyotypic analysis of
HCCs revealed that recurrent regions of copy number change and allelic imbalances are present in 90%
of cases, thus highlighting the possibility for new cancer gene targets reside in these loci [33,34]. In
this context, telomere shortening may favor carcinogenesis by directly facilitating genomic instability.
Telomere shortening plays a pivotal role in inducing genomic alteration first favoring chromosomes
segregation defect. Indeed, shortened telomeres have been associated with the typical karyotipic
alterations in HCC (chromosome 8 alterations), especially in the presence of TP53 mutations [33,35].
Moreover, loss of hTERT has been shown to affect the overall configuration of chromatin and
to diminish the capacity for DNA repair of double strand breaks (DSB) [36]. Therefore, current data
suggest a model whereby telomere shortening drives chromosomal instability during early stages
of hepatic carcinogenesis, while telomerase re-activation is involved in malignant progression, as it
restores chromosomal stability necessary for cellular immortalization.
2.4. Elongation of Telomeres and Telomerase Complex Reactivation during Advance Hepatocarcinogenesis
While the majority of tumors display shortened telomeres compared to non-neoplastic tissues,
nevertheless telomere lengthening has been observed in various tumors at advanced stage, including
colorectal, and head and neck cancers [37]. In HCC tissues, long telomeres and increased telomerase
activity were also shown to be a significant reflection of poor prognostic factors, associated with
clinicopathological features of aggressive behavior [38]. Indeed, HCC tumor progression is associated
with the reactivation of telomerase, which is necessary for the immortalization of the neoplastic
clone [39,40]. Accordingly, hTERT was found upregulated in dysplastic liver nodules and to be more
than 10-fold induced in overt HCC tissue compared to the surrounding non-neoplastic tissue [41]
independently from the etiology of liver disease [42].
On the contrary, a specific gene signature of the Shelterin complex has been identified for each
cause of liver disease. Indeed, Shelterin overexpressed in HCC developed upon HCV infection
or in the presence of alcohol abuse, and displayed a diminished expression in HCC developed
upon HBV infection [5]. In particular, longer telomeres have been observed in HCCs expressing
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markers of stemness, such as CK19, EpCAM and CD133, generally considered more aggressive than
the conventional, negative for these markers [43,44]. It is known that there is heterogeneity in the
expression patterns of stemness-related markers within the same tumors. Interestingly, the analysis of
telomere length among different cells according to EpCAM expression status has shown that longer
telomeres were present in HCC tumor cells that expressed EpCAM, compared to tumor cells that were
EpCAM-negative [45]. Additionally, stemness–related markers were correlated with the expression
of the Shelterin proteins. Increased TPP1, TRF2, RAP1, and POT1 expression were observed in HCC
tissues expressing “stemness”-related markers compared to conventional HCCs, and their expression
was correlated with poorer prognosis and reduced disease-free survival [45]. On the other hand,
shortened telomeres and low POT1 expression have been observed in HCCs expressing HepPar1, a
marker of hepatocytes differentiation. Additionally, Kim et al. [46] demonstrated that TPP1 expression
was correlated with hTERT expression, supporting previous findings indicating TPP1 as a positive
regulator of telomere maintenance that may represent a good target for cancer therapy as it plays a
dominant role in the recruitment of hTERT to telomeres.
Elongation of telomere may also be due to higher expression of DKC1 in HCC compared to
noncancerous liver tissue where the level of the protein was absent or very low. DKC1 expression has
been validated as an independent risk factor for adverse overall mortality, and it was correlated with
advanced HCC clinical stage (grade III–IV) and recurrence independently of hTERT expression [47].
Considering that DKC1 is the direct and conserved transcriptional target of c-myc responsible for
proliferative activity of cancer cells [48], this suggests that the role of DKC1 on cancer progression may
be independent of its involvement in telomerase complex function.
Additionally, elongation of telomeres in 7% of HCC cases is associated with alternative
lengthening of telomeres (ALT), the telomerase-independent telomere maintenance mechanism, which
is thought to be dependent on homologous recombination. The ALT-positive cells are characterized by
telomere length heterogeneity, as well as increased chromosomal instability [49].
2.5. Mechanisms of Reactivation of Telomerase in HCC Tissue
Several mechanisms have been shown to lead to telomerase activation during hepatic
carcinogenesis. hTERT promoter mutations have been described as the most frequent somatic
genetic alteration in HCC, with an overall frequency of 60% in Western countries, in particular
in patients with chronic HCV infection [50,51]. Interestingly, these somatic mutations occur not
only in cancer tissue but in 6%–19% of the cases have been observed also in the early cirrhotic
tissue, while usually somatic mutations in oncogene or oncosuppressor genes occur in a more
advanced stage of tumorigenesis [51,52]. These promoter mutations represent the most important
mechanism of reactivation of telomerase during hepatocarcinogenesis. Indeed, they create new binding
sites for specific transcription factors, which consequently induce hTERT overexpression [53,54].
No promoter mutations have been individuated in studies involving cholangiocarcinoma [52] and
hepatoblastoma [55], while a minority of patients affected by hepatocholangiocarcinoma presented
these kinds of mutations. This evidence suggests that telomerase involvement is dependent on
the origin of the cancer cells [56]. In HCC, due to HBV infection, the reactivation of telomerase is
generally due to the insertion of the HBV virus in hTERT gene, more frequently in the promoter [57,58].
Integration of HBV was detected in 22% of the HBV positive samples, whereas hTERT focal
amplification, another mechanism likely inducing increased telomerase activity, in 6.7% of the cases.
In the same study, hTERT promoter mutations were mutually exclusive with HBV genome integration
in the hTERT locus and were almost mutually exclusive with hTERT focal amplifications [59].
2.6. Telomerase Promotes Hepatic Carcinogenesis by Multiple Pathways
Besides telomere protection and maintenance, several in vitro and in vivo studies in which hTERT
has been exogenously expressed revealed novel telomerase functions in tumorigenesis independently
of hTERC [60]. First, hTERT can act as a transcription factor in the Wnt-β-catenin signaling
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pathway, regulating the expression of Wnt target genes, which play a role in tumorigenesis. Indeed,
hTERT interacts with BRG1, a chromatin remodeler binding to β-catenin and involved in the Wnt
signaling [61], and promotes the expression of several β-catenin target genes in a BRG1-dependent
way. Consistently, hTERT was found to interact with the same promoter elements recognized by
BRG1 and β-catenin [62]. Actually, the relationship between hTERT and the Wnt-β-catenin pathway
is bidirectional: indeed, β-catenin deficient human cell lines showed shorter telomere and reduced
telomerase activity, and hTERT appears as a direct target of β-catenin through the binding to TCF4
transcription factor [63]. Furthermore, hTERT and BRG1 interact with nucleostemin, a GTP-binding
protein overexpressed in stem cells and cancers [64], which is essential to drive transcriptional
programs relevant for the maintenance of the cancer stem cells phenotype [65]. In this case, hTERT
contributes to tumorigenesis increasing the proportion of stem cells within a tumor.
Further functions of hTERT in tumorigenesis are related to its localization in mitochondria. Here,
telomerase plays a role as an RNA-dependent RNA polymerase (RdRP) paired to a mitochondrial
non-coding RNA, the mitochondrial RNA processing endoribonuclease (RMRP) [66]. hTERT represents
the only RdRP identified in mammals and hTERT-RMRP complex leads to the production of
double-stranded RMRP RNA molecules, subsequently processed into 22-nucleotide siRNAs by
RNA-induced silencing complex (RISC) [66]. Since RMRP has several cellular functions, including
mRNA cleavage of cell cycle genes [67], hTERT may influence cellular proliferation, both increasing
cell division and reducing apoptosis, independently of activation of Wnt signaling.
Finally, hTERT can increase cancer cell fitness, improving mitochondrial activity and resistance
to apoptosis. Indeed, mt-TERT, through its reverse transcriptase domain, can provide mt-DNA
replication and repair using mt-tRNAs as the template [68]. Additionally, Sahin et al. [60,69] noticed
that Tert and Terc late generation knockout mice showed a p53-mediated repression of peroxisome
proliferator-activated receptor gγ coactivator-1 α and β (Pgc-1α and Pgc-1β), the master regulators of
mitochondrial physiology and metabolism, resulting in altered mitochondrial biogenesis and function
and increased reactive oxygen species.
2.7. Telomeres and Nonalcoholic Fatty Liver Disease (NAFLD)
Following the epidemic of obesity and type 2 diabetes, NAFLD is becoming the most frequent
liver disease in Western countries. Established risk factors for disease progression in NAFLD include
older age and presence of features of the metabolic syndrome, such as obesity, insulin resistance, and
hypertension. However, progression of liver disease to cirrhosis and HCC is generally limited to the
subgroup of patients who developed non-alcoholic steatohepatitis (NASH), a condition characterized
by active inflammation and fibrosis [70]. Genetic factors have also been shown to influence disease
progression in NAFLD. Besides the most validated factors influencing lipid metabolism, such as the
I148M variant of PNPLA3, the influence of variants involved in fibrogenesis has recently been described.
Genetic data indicate that NAFLD is commonly observed in patients with telomeropathies,
suggesting that steatosis may either be a consequence of hepatocellular senescence, as also observed
in animal models, or a trigger for liver disease progression [10,21]. Fibrosis stage and liver disease
progression are also strictly linked to cell senescence. Consistently, hepatocyte expression of p21,
playing a pivotal role in the induction and maintenance of cellular senescence, was associated with
fibrosis stage in NAFLD and increase liver related morbidity and mortality [71]. Additionally, the
rs762623 variant in the promoter region of Cyclin-dependent Kinase 1A (CDKN1A) gene, encoding for
p21 protein, was associated with the development but not the progression of fibrosis in NAFLD
independently from well-recognized PNPLA3 I148M status [72]. This polymorphism has been
associated with reduced p21 expression by abolishing an E2F transcription factor binding site. Thereby
these data suggest that CDKN1A rs762623 G > A polymorphism favors HSC proliferation by limiting
p21 induction, due to DNA damage and telomere shortening, but it may not predispose to severe
fibrosis because it antagonizes cellular senescence [73]. Interestingly, CDKN1A variants have previously
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been described in association with rapid progression of idiopathic pulmonary fibrosis, another
degenerative condition characterized by cellular senescence and impairment of telomeres [74].
Telomere attrition may also be involved in mediating cancer susceptibility in NAFLD. We reported
the occurrence of HCC in NAFLD in a family where a novel missense hTERT mutation was segregated
with idiopathic familial pulmonary fibrosis and NAFLD. This rare Glu668Asp variant located in the
motif 3c of the reverse transcriptase domain of the protein likely led to reduced telomeres length by
directly interfering with hTERT enzymatic activity [75]. This finding suggested us to investigate the
presence of hTERT germline coding mutations in a cohort of patients who developed HCC without
recognized risk factors (cryptogenic) or were affected only by NAFLD, which, in the absence of other
predisposing conditions, is per se a relatively weak risk factor for progressive liver disease. We observed
a highly significant enrichment of germline coding mutations in NAFLD HCC. In fact, 10% of NASH
HCC were carriers of mutations, while no mutations were identified in 30 NASH cirrhosis and in
healthy controls. The rare mutations modifying the sequence of the protein identified (three missense
and one frameshift) were located in the N-terminal domain of interaction with hTERC or in the catalytic
domain, likely impairing the activity of the telomerase complex. However, the relatively small number
of patients analyzed did not allow for correlation of the presence of hTERT mutations with HCC
prognosis. Additionally, in the same study, we found that telomeres are progressively shortened in
peripheral blood leukocytes of NAFLD HCC patients compared to cirrhosis and controls [76]. These
data point out a possible causal role for telomere attrition and telomerase mutations in influencing
susceptibility towards HCC in NAFLD patients. As telomere shortening was not always correlated
with the presence of hTERT mutations, this suggests that mutations in other genes contributing
to the maintenance of telomeres or epigenetic mechanisms may result in a similar phenotype
(genetic heterogeneity) and contribute to the phenotypic expression of heterozygous hTERT mutations.
3. Conclusions
Telomeres and telomerase play an important role in the onset and progression of liver disease
independently of the underlying etiology. However, the role of telomere attrition and cell senescence
is most likely magnified in NAFLD, where genetic risk factors and ageing have a large impact on
the predisposition to advanced liver damage in combination with acquired risk factors. The role of
telomeres in the pathogenesis of liver disease may be explained by the following hypothesis. Triggering
factors, such as obesity and insulin resistance in the case of NAFLD, induce a condition of chronic
hepatic damage and regeneration characterized by progressive hepatocytes telomere shortening and
senescence. When hepatocytes reach senescence, liver regeneration decreases, but chronic damage
remains. Concomitantly, other cell types, such as HSCs, become activated and form fibrotic tissue in
area of hepatocyte loss. In this context, germline hTERT loss-of-function mutations accelerate telomere
shortening, favoring fibrosis development and thus creating a favorable microenvironment for cancer
onset. Moreover, telomere attrition and germline hTERT loss-of-function mutations may exert a direct
pro-carcinogenic effect by promoting genomic instability, both inducing telomere shortening and
impairing telomerase activity in DNA repair and chromatin organization [36]. Within this context,
the presence of heterozygous mutations does not prevent the reactivation of the telomerase wild type
allele at later stages of carcinogenesis, which is necessary for the indefinite replication of the neoplastic
clone (Figure 2).
Several studies suggest the use of telomerase inhibitors for HCC treatment. These molecules will
hopefully be able to arrest early tumor growth by blocking telomerase, having an almost immediate
effect since they likely act on a phenotype of still short telomeres [77]. Moreover, they could arrest
inflammatory and HSC telomerase activity, and, consequently, telomere elongation, which has been
described as a feature of cirrhotic tissue surrounding tumors [18], thus having a beneficial effect
both on the cirrhotic and the cancer tissue. Additionally, inhibition of telomerase may enhance
chemosensitivity of cancer cells to chemotherapeutic agents [78]. Vice versa, treatment based on
molecules that activate telomerase may be useful at the first stage of liver disease and in patients
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carrying telomerase complex mutations, in order to permit tissue regeneration by avoiding hepatocyte
telomere shortening and senescence. This could be exploited by transplantation of liver cells engineered
for hTERT gene expression, by directly delivering hTERT to the organ, or by small molecules enhancing
telomerase activity. However, to date, it is not known how to manage both the carcinogenic potential
of hTERT-immortalized hepatocytes, and the hepatotoxicity linked to gene delivery [77].
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Figure 2. Hypothesis for telomeres’ role in pathogenesis of nonalcoholic fatty liver disease (NAFLD)
progression toward cirrhosis and hepatocellular carcinoma (HCC). The model shows that, in the
presence of triggering acquired risk factors such as obesity and insulin resistance, the liver undergoes
cycle of damage and regeneration that requires telomerase re-activation. However, degenerative chronic
conditions lead to telomere shortening and fibrosis progression towards cirrhosis, the main risk factor
for HCC. In carriers of t l rase germline loss-of-function mutations, this process is accelerated due
to telomeras inability to elongate telomeres, thus mpairing tissue regenera ion. Moreover, telomerase
mutations may have a direct pro-carcinoge ic effect by inducing genomic instability. Finally, telomere
re-elongation in cancer tissue was triggered by different mechanisms, among which, overexpression of
hTERT is necessary for the immortalization of the neoplastic clone.
Interestingly, both the inhibition and the activation of telomerase may be useful in different stages
of liver dis ase, and, at the same time, may have imp rtant side effects due also to the impairment
of the physiological express on of this gen in other organs and issues. Thus, how to act in order to
modulate telomerase activity remains contr versial. Further studies are nec ssary in order to better
understand the impact of telomeres and tel merase on the different levels of liver disease progression,
and consequently how to act to prevent telomerase related damage.
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